drugset / Trial / NCT02894398
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ / HER2-, who are treated with an aromatase inhibitor or fulvestrant as baseline therapy in combination with palbociclib (Ibrance)
Timeline
- Start
- 2016-09-06
- Primary completion
- 2023-02-15
- Completion
- 2023-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | — |